Due to their involvement in a large scope of chronic diseases such as cardiovascular diseases, cancer, etc. Epigenetic regulatory proteins are hot targets in the field of drug discovery. The capability to track and analyze the epigenetic changes effectively is hugely dependent on one critical tool – antibodies.
Antibodies from BioVision
Due to the lack of antibodies with specificity, sensitivity, accuracy, and consistency, the successful analysis of the epigenetic code to date is limited. BioVision has a number of high quality, multi-application validated antibodies to overcome these limitations.
So regardless of your chosen approach – Chromatin immunoprecipitation (ChIP), Dot Blot, ELISA, Immunofluorescence, Western Blot, Immunoprecipitation – these antibodies will supply you with total confidence to read, write and erase the epigenetic code.
About BioVision Incorporated
BioVision, Inc., is a privately held Life Science company headquartered in the beautiful San Francisco Bay Area.
BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, etc. BioVision's products are currently being sold in more than 60 countries worldwide.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.